Emmaus Life Sciences’ Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition

TORRANCE Calif.: TORRANCE Calif., Dec. 6, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that data on Endari®, the company's prescription L-glutamine oral powder for the treatment of sickle cell disease, has been accepted...

Click to view original post